ORIX Corporation
NYSE:IXFinancial - Credit Services
+$0.45 today
- Market cap
- $36.76B
- Beta
- 0.73
- P/E (TTM)
- 15.7
- EPS (TTM)
- $412.82
- Dividend yield
- 2.42%
Volume 0.30M
Average 0.36M
IX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ORIX CorporationNYSE: IX
Research & Development · Q1 FY2027 · quarter ended Jun 2026
Research & development remains negative
Q1 FY2027 research & development was ¥0, compared with ¥0 a year earlier. Trailing-twelve-month research & development was ¥0.
Context
- Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near ¥0 or moves back toward the trailing-twelve-month quarterly average of ¥0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
JPY · from the income statement
- Latest · FY2026
- 0 JPY
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 0 | — |
| FY2025 | 2025-03-31 | 0 | — |
| FY2024 | 2024-03-31 | 0 | — |
| FY2023 | 2023-03-31 | 0 | — |
| FY2022 | 2022-03-31 | 0 | — |
Research & Development vs competitors
How IX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for IX, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $378.95M USD | — | — | 6.8% | |
| LTM Jun 2026 | ¥0 JPY | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding IX) | — | — | — | 0.0% | |
Competitors are the stored peer set for IX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 2.51T | 2.66T | 2.81T | 2.87T | 3.53T |
| Cost of Revenue | 1.57T | 1.62T | 1.64T | 1.67T | 2.4T |
| Gross Profit | 940.79B | 1.04T | 1.17T | 1.2T | 1.13T |
| Gross Margin | 37.5% | 39.1% | 41.7% | 41.8% | 32.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 522.78B | 555.97B | 627.63B | 646.05B | 0 |
| Operating Expenses | 647.9B | 704.59B | 813.33B | 868.72B | 361.57B |
| Depreciation & Amortization | 320.34B | 340.25B | 364.24B | 399.53B | 404.79B |
| EBITDA | 743.78B | 813.04B | 916.36B | 944.67B | 1.34T |
| EBITDA Margin | 29.7% | 30.5% | 32.6% | 32.9% | 38.0% |
| Operating Income | 292.88B | 335.92B | 360.71B | 331.83B | 770.68B |
| Operating Margin | 11.7% | 12.6% | 12.8% | 11.5% | 21.8% |
| Interest Income | 281.7B | 319.48B | 348B | 0 | 387.62B |
| Interest Expense | 68.23B | 127.62B | 188.33B | 169.05B | 205.58B |
| Other Income / Expenses | 216.56B | 56.26B | 109.26B | 148.64B | (37.55B) |
| Income Before Tax | 509.45B | 392.18B | 469.98B | 480.46B | 733.13B |
| Pre-Tax Margin | 20.3% | 14.7% | 16.7% | 16.7% | 20.8% |
| Income Tax Expense | 186.59B | 95.25B | 131.39B | 128.83B | 247.16B |
| Net Income | 317.38B | 290.34B | 346.13B | 351.63B | 475.04B |
| Net Margin | 12.7% | 10.9% | 12.3% | 12.2% | 13.5% |
| EPS (Basic) | 259.37 | 231.35 | 298.55 | 307.74 | 425.01 |
| EPS (Diluted) | 259.07 | 231.04 | 298.05 | 307.16 | 423.42 |
| Weighted Avg Shares | 1.2B | 1.18B | 1.16B | 1.14B | 1.12B |
| Weighted Avg Shares (Diluted) | 1.2B | 1.18B | 1.16B | 1.14B | 1.12B |
ORIX Corporation
NYSE:IX
Intrinsic Alpha fair value
Locked
Current Price
$33.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.